Table 2. Univariate and multivariate Cox regression for DMFS of patients with HER2 tumours (n = 155).

	Univariate		Multivariate
Factor	HR (95% CI)	p	HR (95% CI)	p
Trastuzumab exposition
No	1
Yes	0.362 (0.167–0.784)	0.010
Trastuzumab exposition
≤292 days/no	1		1
>292 days	0.297 (0.127–0.698)	0.005	0.284 (0.121–0.668)	0.004
Trastuzumab exposition
<6 months/no	1
≥6 months	0.333 (0.147–0.756)	0.009
Trastuzumab exposition
<12 weeks/no	1
≥12 weeks	0.349 (0.158–0.770)	0.009
Trastuzumab exposition
≤9 weeks/no	1
>9 weeks	0.329 (0.149–0.726)	0.006
St. Gallen Consensus treatment
Inadequate	1
Adequate	0.503 (0.222–1.137)	0.099
pN
N−	1		1
N+	2.226 (1.061–4.671)	0.034	2.370 (1.128–4.981)	0.023